No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AVTX Avalo Therapeutics
- 10.5067
- -0.4233-3.87%
Trading Jun 17 11:21 ET
10.87MMarket Cap-206P/E (TTM)
11.3200High10.3000Low10.55KVolume10.9100Open10.9300Pre Close111.88KTurnover1.35%Turnover RatioLossP/E (Static)1.03MShares208.824052wk High-0.10P/B8.23MFloat Cap3.950152wk Low--Dividend TTM782.85KShs Float22031.7120Historical High--Div YieldTTM9.33%Amplitude3.9501Historical Low10.6070Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the
Avalo Therapeutics Files to Sell 22.36M Shares for Holders
Express News | Avalo Therapeutics' Cash On Hand Of Approximately $110M As Of March 31, 2024 With Expected Cash Runway Into 2027
Avalo Therapeutics | 10-Q: Quarterly report
Express News | Avalo Therapeutics Inc - Cash on Hand of Approximately $110 Mln as of March 31, 2024 With Expected Cash Runway Into 2027
Express News | Avalo Therapeutics Q1 Pretax Profit USD -121.283 Million
Comments
$Avalo Therapeutics(AVTX.US$
Chi chif lao wai cheo? = They block Short why trade 😭😭😭😭😭
Chi chif lao wai cheo? = They block Short why trade 😭😭😭😭😭
1
$Avalo Therapeutics(AVTX.US$Avalo Therapeutics Inc expected to post a loss of $1.18 a share - Earnings Preview
1
1
$Avalo Therapeutics(AVTX.US$ worth to buy some?
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg